By DAVID GELLES
Pentwater Capital Management, which owns about 1.3 percent of Allergan’s shares, sent a letter to the company’s board questioning its recent actions regarding a bid from Valeant Pharmaceuticals and William A. Ackman.
Published: September 26, 2014 at 4:00AM
from NYT Business Day http://ift.tt/YjVO1d
from WordPress http://ift.tt/1Bh4O3J
via Hadi Aboukhater
No comments:
Post a Comment